Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.

International Journal of Hematology
J KurodaT Maekawa

Abstract

Since a variety of cell intrinsic and extrinsic molecular abnormalities cooperatively promote tumor formation in multiple myeloma (MM), therapeutic approaches that concomitantly target more than one molecule are increasingly attractive. We herein demonstrate the anti-myeloma effect of a cephalotaxus alkaloid, homoharringtonine (HHT), an inhibitor of protein synthesis, through the induction of apoptosis. HHT significantly reduced Mcl-1, a crucial protein involved in myeloma cell survival, in all three myeloma cell lines examined, whereas certain BH3-only proteins, such as Bim, Bik, and Puma, remained unchanged following HHT treatment, and their expression levels depended on the cell type. HHT also reduced the levels of c-FLIP(L/S), activated caspase-8, and induced active truncated-Bid. Thus, HHT-induced apoptosis appears to be mediated via both intrinsic and extrinsic apoptosis pathways, and the resultant imbalance between BH3-only proteins and Mcl-1 may be pivotal for apoptosis by HHT. In addition, HHT treatment resulted in reduced levels of beta-catenin and XIAP proteins, which also contribute to disease progression and resistance to chemotherapy in MM. In combination, HHT enhanced the effects of melphalan, bortezomib, and ABT...Continue Reading

References

Jul 1, 1997·The EMBO Journal·H AberleR Kemler
Dec 1, 1999·Cell Death and Differentiation·P G EkertD L Vaux
Dec 18, 2001·Cancer·H M KantarjianS M O'Brien
Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
May 7, 2003·International Journal of Hematology·Shinsuke Iida, Ryuzo Ueda
Oct 25, 2003·Cell Death and Differentiation·K HellD W Nicholson
Apr 7, 2004·Proceedings of the National Academy of Sciences of the United States of America·Patrick W B DerksenSteven T Pals
Sep 3, 2004·Human Pathology·Jeong Hee Cho-VegaL Jeffrey Medeiros
Oct 2, 2004·European Journal of Immunology·Patricia Gomez-BougieMartine Amiot
Oct 6, 2004·British Journal of Haematology·S JagannathK C Anderson
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Angela Dispenzieri, Robert A Kyle
Apr 29, 2006·Cell Death and Differentiation·V LabiA Villunger
Jun 13, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Constantine S MitsiadesKenneth C Anderson
Jul 4, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ulrich DenzMonika Engelhardt
Sep 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Junya KurodaAndreas Strasser
Jan 4, 2007·The Journal of Biological Chemistry·Kenneth W Adams, Geoffrey M Cooper
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoichi TanakaToshio Matsumoto
Apr 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Kumar SukhdeoDaniel R Carrasco
Jul 7, 2007·Leukemia & Lymphoma·Yin-Jun LouJie Jin
Jul 21, 2007·Annals of Hematology·Xiudi YangWenbin Qian
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson

❮ Previous
Next ❯

Citations

Jan 7, 2014·Journal of Hematology & Oncology·Shuqing Lü, Jianmin Wang
Sep 16, 2011·Expert Opinion on Pharmacotherapy·Theo Daniel KimPhilipp le Coutre
Jul 24, 2013·Expert Opinion on Pharmacotherapy·Aziz NazhaAlfonso Quintás-Cardama
Nov 22, 2008·Critical Reviews in Oncology/hematology·Junya Kuroda, Masafumi Taniwaki
Feb 9, 2016·Expert Review of Hematology·Yasmin RosshandlerHanna Jean Khoury
Dec 17, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Akihiro WatariMasuo Kondoh
Sep 10, 2009·Cancer·Alfonso Quintás-CardamaJorge Cortes
Dec 20, 2013·American Journal of Clinical Oncology·Myke R GreenKaren M Fancher
Jun 21, 2012·Natural Product Reports·Hajer Abdelkafi, Bastien Nay
Sep 27, 2012·Molecular Cancer Therapeutics·Yuji ShimuraMasafumi Taniwaki
Oct 29, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zachary J WalkerDaniel W Sherbenou
Nov 13, 2020·Drug Design, Development and Therapy·Yanyu ZhangXing Cui
May 5, 2021·Chinese Journal of Natural Medicines·Da-Cheng HaoGuang-Bo Ge

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis